Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 7/20 | 0.84 |
| ▸ | KDR | P35968 | 7/20 | 0.64 |
| ▸ | KIF5B | P33176 | 4/20 | 0.64 |
| ▸ | EGFR | P00533 | 9/20 | 0.61 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.60 |
| ▸ | JAK3 | P52333 | 2/20 | 0.60 |
| ▸ | GAK | O14976 | 1/20 | 0.60 |
| ▸ | STK10 | O94804 | 1/20 | 0.60 |
| ▸ | FLT3 | P36888 | 1/20 | 0.60 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.60 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.60 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.60 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.60 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.60 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.60 |
| ▸ | LCK | P06239 | 3/20 | 0.58 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.57 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.57 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.57 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4383397 | 0.92 | RET (0.70) | RETKDRKIF5BEGFRRIPK2 | |
| SCHEMBL8976728 | 0.91 | RET (1.00) | RETKDRKIF5BEGFRRIPK2 | |
| Hydrochloric Acid SCHEMBL4377353 | 0.91 | RET (0.69) | RETKDRKIF5BEGFRRIPK2 | |
| SCHEMBL15052504 | 0.87 | BRAF (0.76) | RETEGFRRAF1BRAF | |
| SCHEMBL11953092 | 0.86 | RET (0.67) | RETKDRKIF5BEGFRRIPK2 | |
| SCHEMBL6030630 | 0.83 | RET (0.58) | RETKDRKIF5BEGFRRIPK2 | |
| SCHEMBL8561433 | 0.82 | RET (0.83) | RETKDRKIF5BEGFRRIPK2 | |
| SCHEMBL20792806 | 0.81 | EGFR (0.87) | RETKDRKIF5BEGFRRIPK2 | |
| Hydrochloric Acid SCHEMBL4371602 | 0.81 | RET (0.80) | RETKDREGFRRIPK2LCK | |
| Hydrochloric Acid SCHEMBL8904802 | 0.81 | RET (0.81) | RETKDRKIF5BEGFRRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | disclosed |
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | disclosed |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | STOKES ELAINE S E (GB) | 2012-08-02 | — | — | US | disclosed |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | STOKES ELAINE S E (GB) | 2012-08-02 | — | — | US | disclosed |
| EP-2050744-A1 | Quinazoline derivatives as angiogenesis inhibitors | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| EP-2050744-A1 | Quinazoline derivatives as angiogenesis inhibitors | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| US-7074800-B1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2006-07-11 | — | — | US | disclosed |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB | 2006-01-05 | — | — | US | disclosed |
| EP-1553097-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE | AstraZeneca AB (SE) | 2005-07-13 | — | — | EP | disclosed |
| EP-1154774-B1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | EP | disclosed |
| EP-1154774-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000047212-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | VEGFA, FLT1, KDR | RET 637/4885KDR 3/4885KIF5B 1611/4885 |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | FLT4, NOS3, FLT1 | RET 1047/4885KDR 4/4885KIF5B 3583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.